EpCAM Expression in Lymph Node Metastases of Urothelial Cell Carcinoma of the Bladder:A Pilot Study by van der Fels, Christa A. M. et al.
  
 University of Groningen
EpCAM Expression in Lymph Node Metastases of Urothelial Cell Carcinoma of the Bladder
van der Fels, Christa A. M.; Rosati, Stefano; de Jong, Igle J.
Published in:
International Journal of Molecular Sciences
DOI:
10.3390/ijms18081802
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van der Fels, C. A. M., Rosati, S., & de Jong, I. J. (2017). EpCAM Expression in Lymph Node Metastases
of Urothelial Cell Carcinoma of the Bladder: A Pilot Study. International Journal of Molecular Sciences,
18(8), [1802]. https://doi.org/10.3390/ijms18081802
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
 International Journal of 
Molecular Sciences
Article
EpCAM Expression in Lymph Node Metastases
of Urothelial Cell Carcinoma of the Bladder:
A Pilot Study
Christa A. M. van der Fels 1,*, Stefano Rosati 2 and Igle J. de Jong 1
1 Department of Urology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen,
The Netherlands; i.j.de.jong@umcg.nl
2 Department of Pathology, University Medical Center Groningen, University of Groningen,
9700 RB Groningen, The Netherlands; s.rosati@umcg.nl
* Correspondence: c.a.m.van.der.fels@umcg.nl; Tel.: +31-50-361-28-01; Fax: +31-50-361-96-07
Received: 17 July 2017; Accepted: 16 August 2017; Published: 18 August 2017
Abstract: In this retrospective pilot study, the feasibility of the epithelial cell adhesion molecule
(EpCAM) as an imaging target for lymph node (LN) metastatic disease of urothelial cell carcinoma
(UCC) of the bladder was investigated. LN metastases and LNs without metastases of patients who
underwent pelvic lymph node dissection because of muscle invasive bladder cancer (MIBC) were
used. Primary tumors of the same patients were used from cystectomy specimen, transurethral
resections, and biopsies. A pathologist, blinded to clinical data, scored EpCAM immunoreactivity.
This method determines a total immunostaining score, which is the product of a proportion score and
an intensity score. EpCAM expression was observed in 19/20 (95%) LNs with UCC metastases and
in 11/12 (92%) of the primary tumors. EpCAM expression was absent in 14/14 (100%) LNs without
metastases. Median EpCAM expression (TIS) in LN metastases was 5 (IQR 2.0–8.0) and in the primary
tumors 6 (IQR 2.3–11.0). Based on the absence of staining in LNs without metastases, EpCAM show
high tumor distinctiveness. EpCAM seems to be a feasible imaging target in LN metastases of UCC
of the bladder. Pre- and perioperative visualization of these metastases will improve disease staging
and improve the complete resection of LN metastases in MIBC.
Keywords: urothelial cell carcinoma; immunohistochemistry; lymph node metastases; EpCAM
1. Introduction
Imaging is needed to determine local extension and lymph node status of muscle invasive bladder
cancer (MIBC) [1]. C-Choline PET/CT have been proved to be more sensitive to assess the presence of
lymph node metastases in patients with bladder cancer, compared to contrast-enhanced CT. However,
it still lacks sensitivity (10–59%) and specificity (64–90%) in diagnostic information in preoperative
nodal staging of patients with invasive BC [2,3]. To date, FDG PET/CT seems to be the best performing
method to detect lymph node metastases, with the highest sensitivity and specificity compared to
other imaging modalities [4,5]. However, lymph node metastatic lesions less than 1 cm can still not
be detect by this method [4]. In addition, the change in management is relatively small [1,6]. Pelvic
lymph node dissection remains the gold standard for nodal staging.
New diagnostic imaging modalities that can assess lymph node metastases of MIBC more properly
than the available current modalities are preferred. Improving the identification of lymph node
metastases will give us a more reliable staging in disease management. Besides, improving the
identification of lymph node metastases perioperative will be helpful to improve the number of lymph
nodes removed. Retrospective studies previously suggested that increasing lymph node retrieval
may have a direct therapeutic effect either by more properly assigning a pathological category or by
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truly removing micrometastatic disease. Increasing nodal counts has an association with improved
outcomes after radical cystectomy, specifically in those with node-positive disease [7–9].
By adding a specific target to molecular imaging modalities, tumor specific imaging modalities
could be obtained. Previous target selection criteria scoring systems criticized multiple proteins as
potential biomarkers for tumor targeted imaging techniques [10]. Because of its characteristics that
resulted in a high total score, EpCAM seems a suitable candidate for these purposes [10]. Epithelial
cell adhesion molecule (EpCAM; syn. GA733-2, TACSTD1, KSA, EGP40, CD326, 17-1A, HEA125,
MK-1, EGP-2, EGP-34, ESA, KS1/4), is a transmembrane glycoprotein expressed exclusively in normal
epithelial tissues and epithelial-derived neoplasms [11]. Immunohistochemical studies revealed that
EpCAM is overexpressed on various carcinoma cells in breast, prostate, ovarian, lung, colon, renal, and
gastric cancer [12]. The expression rates of EpCAM in urothelial cell carcinoma (UCC) of the bladder
varies between 27% and 99% in different studies. Besides, EpCAM expression has also been found in
normal urothelial cells [11,13,14]. Because of the wide variance of EpCAM expression in the primary
tumor, the expression of EpCAM in lymph node metastases of urothelial cell bladder cancer has not
been determined yet, as far as we know. Previously, EpCAM expression was highly found in lymph
node metastases of prostate cancer [15,16] and lymph node metastases of urothelial carcinomas of the
renal pelvis [17].
In the current study, the expression of EpCAM in lymph node metastases of UCC of the bladder
was compared to the expression of EpCAM in matched lymph nodes without metastases and to the
expression of EpCAM in the matched invasive primary bladder tumor.
2. Results
2.1. Immunoreactivity
Lymph node metastases and primary bladder tumor samples showed the typical histologic aspect
of UCC, without differentiation of other tumor types. After immunohistochemistry, all 34 lymph nodes
were available for analyses. Two (2 out of 14) of the primary tumor samples (patient 4: transurethral
biopsy and patient 10: cystectomy specimen, Table 1) only showed CIS and pTa and no invasive tumor.
Since invasive tumor is needed for a proper comparison between primary tumor and matched lymph
nodes, these samples were not suitable for evaluation. Scoring of EpCAM immunoreactivity per lymph
node and primary tumor sample is presented in Table 1.
EpCAM expression was observed in 19 out of 20 (95%) lymph nodes with UCC metastases.
Median EpCAM expression (TIS) in lymph node metastases was 5.0 (inter quartile range: 2.0–8.0).
Median proportion score was 3.0 (inter quartile range: 2.0–4.0) and median intensity score was 1.5
(inter quartile range: 1.0–2.0). If PS was low (1–2), IS was low too (1). Strong intensity score was
only seen in two lymph nodes. EpCAM expression was absent in 14 out of 14 (100%) lymph nodes
without metastases.
EpCAM expression was observed in 11 out of 12 (92%) primary UCC of the bladder. Median
EpCAM expression (TIS) in primary tumor was 6.0 (inter quartile range 2.3–11.0). Median proportion
score was 3.0 (inter quartile range: 1.5–4.0) and median intensity score was 2.0 (inter quartile range:
1.0–2.8). If PS was low (1–2), IS was low too (1).
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Table 1. Scoring EpCAM immunoreactivity.
Patient Age (Years) Sex Stage LN Excised LN+ Tissue Type PS IS TIS
1 39 M T2 2 1 Primary bladder tumor 3 2 6
Lymph node normal 0 0 0
Lymph node metastasis 3 1 3
2 77 M T2 15 3 Primary bladder tumor 4 1 4
Lymph node normal 0 0 0
Lymph node metastasis 4 2 8
Lymph node metastasis 3 2 6
3 79 F T2 17 1 Primary bladder tumor 4 3 12
Lymph node normal 0 0 0
Lymph node metastasis 4 3 12
4 78 M Tis 5 1 Primary bladder tumor - - -
Lymph node normal 0 0 0
Lymph node metastasis 4 3 12
5 69 M T2 16 2 Primary bladder tumor 0 0 0
Lymph node normal 0 0 0
Lymph node metastasis 1 1 1
6 55 M T2 3 1 Primary bladder tumor 4 3 12
Lymph node normal 3 2 6
Lymph node metastasis 0 0 0
7 67 M T2 8 4 Primary bladder tumor 3 1 3
Lymph node normal 0 0 0
Lymph node metastasis 2 1 2
Lymph node metastasis 4 1 4
8 61 F T2 8 3 Primary bladder tumor 4 2 8
Lymph node normal 0 0 0
Lymph node metastasis 4 2 8
Lymph node metastasis 4 1 4
9 43 F T2 22 5 Primary bladder tumor 1 1 1
Lymph node normal 0 0 0
Lymph node metastasis 2 1 2
10 68 M T2 15 3 Primary bladder tumor - - -
Lymph node normal 0 0 0
Lymph node metastasis 2 1 2
Lymph node metastasis 2 1 2
11 64 F T2 12 3 Primary bladder tumor 1 2 2
Lymph node normal 0 0 0
Lymph node metastasis 1 1 1
Lymph node metastasis 0 0 0
12 64 M T2 16 2 Primary bladder tumor 3 2 6
Lymph node normal 0 0 0
Lymph node metastasis 4 2 8
13 48 F T2 7 1 Primary bladder tumor 4 3 12
Lymph node normal 0 0 0
Lymph node metastasis 3 2 6
14 78 M T2 9 4 Primary bladder tumor 3 2 6
Lymph node normal 0 0 0
Lymph node metastasis 3 2 6
Lymph node metastasis 4 2 8
Stage: T stage primary tumor, PS: Proportion Score, IS: Intensity Score, TIS: Total Immunostaining Score.
2.2. Staining Pattern
EpCAM brown staining was seen membranous in UCC cells of lymph nodes. Figure 1. Only one
lymph node with UCC metastasis did not show EpCAM expression at all. The rest of the lymph node
metastases showed EpCAM brown staining in different proportion scores. Figure 2. EpCAM brown
staining was also seen membranous in UCC cells in primary tumor samples. Figure 3.
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Figure 1. Normal lymph node without EpCAM expression and lymph node metastases with EpCAM 
expression with intensity score 1: weak; 2: moderate; and 3: strong. Original magnification: 200×. 
Figure 2. Lymph node metastasis without EpCAM expression. Lymph node metastases with EpCAM 
expression with proportion score 2: 10–50%; 3: 51–80%; and 4: >80%. Original magnification: 200×. 
Figure 1. Normal lymph node without EpCAM expression and lymph node metastases with EpCAM
expression with intensity score 1: weak; 2: moderate; and 3: strong. Original magnification: 200×.
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Figure 3. Primary tumor in urinary bladder without EpCAM expression and with EpCAM expression 
with intensity score 1: weak; 2: moderate; and 3: strong. Original magnification: 200×. 
3. Discussion 
The current study shows a high EpCAM expression in lymph node metastases of UCC of the 
bladder (19 out of 20), and absent of staining for EpCAM in lymph nodes without metastases (0 out 
of 14). However, there was a variance in the proportion and intensity of the expression amongst 
different lymph nodes. Previously, “overexpression” of EpCAM was defined as a TIS > 4 [11,18]. In 
addition, four subgroups of overexpression have been defined: TIS 0, no expression; TIS 1–4, weak 
expression; TIS 6 and 8, moderate expression; TIS 9 and 12, intense expression [11,19]. According to 
these defined subgroups, from lymph node metastases; 1 (5%) did not show expression; 9 (45%) 
showed only weak expression; 6 (30%) showed moderate expression; and 4 (20%) showed intense 
expression in the current study. However, these subgroups were defined in order to evaluate the 
predictive value of EpCAM expression on survival in clinical trials and to predict therapy response 
in patients treated with EpCAM-specific targeting agents [18–20]. About the diagnostic and 
prognostic value of EpCAM expression in UCC of the bladder, Bryan et al. showed that elevated 
urinary EpCAM was an independent prognostic factor for bladder cancer survival [21]. Brunner et 
al. also previously showed that EpCAM expression is associated with advanced stage, high grade 
and poor survival in UCC of the bladder [17]. In our study, the feasibility of EpCAM as an imaging 
target was determined and not for risk stratification. Due to the low number of patients (n = 14), the 
power of the statistics would be too weak to correlate staining intensity with clinicopathological 
parameters and outcomes after surgery. Another limitation of our study is that immunoreactivity 
was only scored by one pathologist. 
EpCAM expression in lymph nodes was compared to the expression of EpCAM in the matched 
primary bladder tumor. All but one (11 out of 12) of the primary tumors showed EpCAM expression, 
however, also with variable proportion and intensity scores. TIS in the primary tumor was not always 
the same as TIS in the matched lymph node metastasis of the same patient. Two lymph node 
metastases of one patient showed TIS in the same subgroup, except for the lymph node that did not 
show expression at all. Spizzo et al. observed EpCAM negativity (TIS 0) in 56% of urothelial 
carcinomas and an EpCAM overexpression rate (TIS > 4) of 27% [11]. This is a major difference with 
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bladder (19 out of 20), and absent of stai ing for E CAM in lymph nodes without metastases (0 out
of 14). However, th re was a variance in the pr portion and intensity of the expression amongst
differe t lymph nodes. Previously, “overexpression” of EpCAM was defined as a TIS > 4 [11,18].
In addition, four subgroups of overexpression have been defi ed: TIS 0, no expression; TIS 1–4, weak
expressio ; TIS 6 and 8, moderate expression; TIS 9 nd 12, intense expressi n [11,19]. According to
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only weak expression; 6 (30%) showed moderate expression; and 4 (20%) showed intens expression
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that EpCAM expression is associate with advanced stage, high grade and poor survival in UCC of
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be too weak to c rrelate t ining int nsity wit clinicopathological parameters and o tc mes after
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t t of one patient showed TIS in the same subgroup, except for the lymph node that did
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not show expression at all. Spizzo et al. observed EpCAM negativity (TIS 0) in 56% of urothelial
carcinomas and an EpCAM overexpression rate (TIS > 4) of 27% [11]. This is a major difference with
the expression that was found in our primary tumors. More data have to be collected and our results
should also be confirmed by using a second primary antibody. On the other hand, Spizzo et al. did
not describe whether their UCCs were invasive or non-invasive. All evaluated tumors in our study
were invasive, which could explain the differences of EpCAM expression in the primary tumor as
well. Other studies showed a strong, circumferential membrane reaction of EpCAM in carcinoma cells
of the urinary bladder. However, EpCAM expression was also seen on normal urothelial tissue in
these studies. EpCAM expression on normal urothelial tissue was described as limited to the basal
layers of the bladder and was not seen in superficial umbrella cells. Lymph node specimens of UCCs
were not available [14,22]. In our study, strong positive staining of EpCAM in some parts of normal
urothelial cells of the bladder was seen in basal layers, but also weak staining was seen in umbrella
cells. Therefore, EpCAM does not seem suitable as a diagnostic target for primary UCC of the bladder.
As far as we know, the current study is the first that assessed EpCAM expression in lymph
node metastases of UCC of the bladder compared to matched normal lymph nodes and the matched
primary tumor. EpCAM showed a high sensitivity (95%) and specificity (100%) in lymph nodes
and also a high sensitivity (92%) in the primary bladder tumor. Antibodies against EpCAM have
previously been used to visualize micrometastases in lymph nodes of papillary thyroid cancer and
non-small-cell lung cancer by immunohistochemistry. These lymph nodes were found to be free of
metastases at routine histopathological examination, [23,24] showing the use of antibodies against
EpCAM was highly sensitive in the detection of lymph node metastases. Previous studies also proved
that antibodies against EpCAM do not react with lymphoid tissue [25,26]. The absence of EpCAM
overexpression in normal lymph nodes supports the use of EpCAM as a target for bladder cancer
lymph node metastases. Antigen-based targeted imaging could be useful to rule out (micro)metastases
prior to radical cystectomy; or to use perioperatively to remove these metastases more properly.
4. Materials and Methods
4.1. Patient Samples
Samples of primary invasive UCC of the bladder, lymph node metastases of UCC of the bladder
and matched lymph nodes without metastases of the same patients were retrieved from the archives
of the Department of Pathology of University Medical Center, Groningen. Only lymph nodes with
an extensive amount of metastases were useful. Formalin-fixed, paraffin-embedded blocks of small
lymph nodes with only micro metastases were not suitable to cut into 4 mm thick sections for the use of
immunohistochemistry. A total 20 lymph node metastases of 14 patients who underwent pelvic lymph
node dissection because of MIBC were available as well as lymph nodes without metastases of the
same patients (n = 14). Primary tumors of these patients were taken from cystectomy specimen (n = 7),
transurethral resection of the bladder tumor (n = 6) and transurethral biopsy of the bladder tumor
(n = 1). All tissue specimens were anonymously coded. According to Dutch law, no further Institutional
Review Board approval was required (http://www.federa.org/). Trial registration number (UMCG
Research Register): 201600084 (date registered: 02/04/2016).
4.2. Experimental Setup
EpCAM expression was determined by immunohistochemistry. Normal colon was used as the
positive control and omission of the primary antibody on normal colon samples served as a negative
control. After deparaffinization with xylene baths and decreasing grades of alcohol, antigen retrieval
was performed by incubation with 0.1% protease for 30 min at room temperature. Endogeneous
peroxidase was blocked with 0.3% hydrogen peroxide in PBS for 20 min in dark. Slides were incubated
with primary mouse monoclonal AB anti-EpCAM (clone VU-1D9, Leica Biosystems, Newcastle, UK),
and diluted at 1:100 in 1% BSA/PBS for 1 h at room temperature. In the secondary step, slides
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were incubated with rabbit anti-mouse AB conjugated to polymer-horseradish peroxidase (DAKO,
Glostrup, Denmark), and diluted at 1:100 in 1% BSA/PBS with 1% AB serum. In the tertiary step,
goat anti-rabbit AB conjugated to polymer-horseradish peroxidase (DAKO, Glostrup, Denmark) was
used, and diluted at 1:100 in 1% BSA/PBS with 1% AB serum. Secondary and tertiary antibodies were
incubated for 30 min at room temperature. After every step, slides were washed with PBS and dried.
Next, slides were immersed for 10 min in a solution of 0.05% 3,3′-diaminobenzidine (Sigma-Aldrich,
Steinheim, Germany) and 0.03% hydrogen peroxide in PBS in dark for visualization of the signal as
brown staining. After washing with demineralized water, slides were slightly counterstained with
hematoxylin, dehydrated by increasing grades of alcohol and when dried, mounted with Tissue Tek
film (Sakura Finetek, Leiden, The Netherlands).
4.3. Assessment of Staining Patterns
All samples were scored in total for EpCAM immunoreactivity by a pathologist (SR) blinded to
clinical and pathological data, according to a previous established method [11]. This method consisted
of a Proportion Score (PS) and an Intensity Score (IS), together resulting in a Total Immunostaining
Score (TIS). The PS represents the estimated amount of positively stained cells (0, none; 1, <10%, 2,
10–50%; 3, 51–80%; 4, >80%). The IS describes the estimated staining intensity (0, no staining; 1, weak;
2, moderate; 3, strong). Specimens in which one or more tumor areas with different staining intensities
were present were scored for the most prevalent intensity. The TIS (TIS = PS × IS) ranges from 0 to 12
with 9 possible values (0, 1, 2, 3, 4, 6, 8, 9, and 12) [11].
4.4. Data Analysis
Descriptive analyses were used to describe the results and are shown as median score. SPSS
statistics (version 23.0 for Windows, IBM Corp., Armonk, NY, USA) was used for analyses.
5. Conclusions
In conclusion, EpCAM shows high tumor distinctiveness, because of the absence of staining in
LNs without metastases. Based on this study, EpCAM could be used as an imaging target for bladder
cancer lymph node metastases. Pre- and perioperative visualization of these metastases will improve
disease staging and improve the complete resection of LN metastases in MIBC. Prospective clinical
trials are needed to confirm the current results.
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Abbreviations
MIBC Muscle invasive bladder cancer
LN Lymph node
TIS Total immunostaining score
PS Proportion score
IS Intensity score
UCC Urothelial cell carcinoma
PBS Phosphate buffered saline
BSA/PBS Bovine serum albumin/phosphate buffered saline
AB Antibody
EpCAM Epithelial cell adhesion molecule
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